Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery

Nature Reviews Drug Discovery

Volumn 1, Issue 3, 2002, Pages 198-210

  Christopoulos, Arthur ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; ALCOHOL; ALKALOID; ANESTHETIC AGENT; ARACHIDONIC ACID; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA CARBOLINE; CELL SURFACE RECEPTOR; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE; GLYCINE; GLYCINE RECEPTOR; HISTAMINE; IFENPRODIL; IVERMECTIN; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PHENCYCLIDINE; PICROTOXIN; POLYAMINE; PURINE P2X RECEPTOR; SEROTONIN; STEROID; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; ZINC; DRUG;

ALLOSTERISM; BINDING AFFINITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL MODEL; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; REVIEW; ANIMAL; BINDING SITE; CHEMISTRY; HUMAN; KINETICS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; ANIMALS; HUMANS; KINETICS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036490942     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd746     Document Type: Review

References (131)

1. Ehrlich, P. The Croonian Lecture: on immunity, with special reference to cell life. Proc. R. Soc. Lond. B 66, 424-448 (1900).
2. Langley, J. N. The Croonian Lecture - on nerve endings and excitable substances in cells. J. Physiol. (Lond.) 34, 170-194 (1906).
3. Drews, J. Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
4. Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15, 598-611 (2001).
5. Kenakin, T. P. Pharmacologic Analysis of Drug-Receptor Interaction (Lippincott-Raven, Philadelphia, 1997).
6. Frauenfelder, H., Parak, F. & Young, R. D. Conformational substates in proteins. Annu. Rev. Biophys. Biophys. Chem. 17, 451-479 (1988).
7. Frauenfelder, H., Sligar, S. G. & Wolynes, P. G. The energy landscapes and motions of proteins. Science 254, 1598-1603 (1991).
8. Frauenfelder, H. Proteins - paradigms of complex systems. Experientia 51, 200-203 (1995).
9. Colquhoun, D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125, 924-947 (1998).
10. Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423 (2000).
11. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. (in the press).
12. Ehlert, F. J., Roeske, W. R., Gee, K. W. & Yamamura, H. I. An allosteric model for benzodiazepine receptor function. Biochem. Pharmacol. 32, 2375-2383 (1983).
13. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
14. Lazareno, S. & Birdsall, N. J. M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48, 362-378 (1995).
15. 2 receptors. Eur. J. Pharmacol. 316, 27-32 (1996).
16. 2A-adrenergic receptor. Mol. Pharmacol. 53, 916-925 (1998).
17. Ehlert, F. J. Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium. J. Pharmacol. Exp. Ther. 247, 596-602 (1988).
18. Christopoulos, A. in Current Protocols in Pharmacology (ed. Enna, S. J.) 1.22.1-1.22.40 (John Wiley & Sons, New York, 2000).
19. Birdsall, N. J. M. et al. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol. Pharmacol. 55, 778-786 (1999).
20. Birdsall, N. J. M., Lazareno, S. & Matsui, H. Allosteric regulation of muscarinic receptors. Prog. Brain Res. 109, 147-151 (1996).
21. Galzi, J.-L. & Changeux, J.-P. Neurotransmitter-gated ion channels as unconventional allosteric proteins. Curr. Opin. Struct. Biol. 4, 554-565 (1994).
22. A receptors. Trends Pharmacol. Sci. 16, 162-168 (1995).
23. Changeux, J. P. & Edelstein, S. J. Allosteric receptors after 30 years. Neuron 21, 959-980 (1998).
24. A receptor diversity emerges a unified vision of GABAergic inhibition. Annu. Rev. Pharmacol. Toxicol. 38, 321-350 (1998).
25. A receptor subtypes. Nature 401, 796-800 (1999).
26. A receptors. Trends Pharmacol. Sci. 18, 425-429 (1997).
27. Costa, E. & Guidotti, A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. 17, 192-199 (1996).
28. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22, 188-194 (2001).
29. Hebert, T. E. & Bouvier, M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem. Cell Biol. 76, 1-10 (1998).
30. Devi, L. A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 22, 532-537 (2001).
31. 1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88-98 (1995).
32. 2 muscarinic acetylcholine receptor. Mol. Pharmacol. 45, 983-990 (1994).
33. Ellis, J. Allosteric binding sites on muscarinic receptors. Drug Dev. Res. 40, 193-204 (1997).
34. Gnagey, A. L., Seidenberg, M. & Ellis, J. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol. Pharmacol. 56, 1245-1253 (1999).
35. Ellis, J. & Seidenberg, M. Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol. Pharmacol. 58, 1451-1460 (2000).
36. Buller, S., Zlotos, D. P., Mohr, K. & Ellis, J. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkanebisammonium ligands. Mol. Pharmacol. 61, 160-168 (2002).
37. Pagano, A. et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 275, 33750-33758 (2000).
38. Knoflach, F. et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl Acad. Sci. USA 23, 13402-13407 (2001).
39. Christopoulos, A., Lanzafame, A. & Mitchelson, F. Alosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Physiol. 25, 184-194 (1998).
40. 7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem. Pharmacol. 57, 171-179 (1999).
41. Lazareno, S., Gharagozloo, P., Kuonen, D., Popham, A. & Birdsall, N. J. M. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic recptors: radioligand binding studies. Mol. Pharmacol. 53, 573-589 (1998).
42. 2A adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol. 60, 669-676 (2000).
43. B receptors by 2,6-ditert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol. 60, 963-971 (2001).
44. Carroll, F. Y. et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 59, 965-973 (2001).
45. 2+-sensing receptor. Trends Pharmacol. Sci. 21, 401-407 (2000).
46. Kollias-Baker, C. et al. Allosteric enhancer PID 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ. Res. 75, 961-971 (1994).
47. Christopoulos, A. & Mitchelson, F. Use of a spreadsheet to quantitate the equilibrium binding of an allosteric modulator. Eur. J. Pharmacol. 355, 103-111 (1998).
48. Kostenis, E. & Mohr, K. Composite action of allosteric modulators on ligand binding. Trends Pharmacol. Sci. 17, 443-444 (1996).
49. Christopoulos, A. in Current Protocols in Pharmacology (ed. Enna, S. J.) 1.21.1-1.21.45 (John Wiley & Sons, New York, 2000).
50. Litschig, S. et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55, 453-461 (1999).
51. Thomas, E. A., Carson, M. J., Neal, M. J. & Sutcliffe, J. G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl Acad. Sci. USA 94, 14115-14119 (1997).
52. 7 receptors. Biochem. Pharmacol. 58, 1807-1813 (1999).
53. Lutz, M. & Kenakin, T. Quantitative Molecular Pharmacology and Informatics in Drug Discovery (John Wiley & Sons, New York, 1999 ).
54. Lazareno, S. in Receptor-Based Drug Design (ad. Leff, P.) 49-77 (Marcel Dekker, New York, 1998).
55. Arunlakshana, O. & Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14, 48-57 (1959).
56. Kenakin, T. P. & Boselli, C. Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic response in rat trachea. J. Pharmacol. Exp. Ther. 250, 944-952 (1989).
57. 2 muscarine receptors. Mol. Pharmacol. 46, 105-114 (1994 ).
58. Christopoulos, A. & Mitchelson, F. Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J. Pharm. Pharmacol. 49, 781-786 (1997).
59. + exchange. J. Biol. Chem. 262, 12387-12392 (1987).
60. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38, 939-949 (1990).
61. 2 receptors. Mol. Pharmacol. 51, 674-682 (1997).
62. Kostenis, E. & Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol. Sci. 17, 280-283 (1996).
63. Monod, J. & Jacob, F. General conclusions: teleonomic mechanisms in cellular metabolism, growth, and differentiation. Cold Spring Harb. Symp. Quant. Biol. 26, 389-401 (1961).
64. Monod, J., Changeux, J.-P. & Jacob, F. Allosteric proteins and cellular control systems, J. Mol. Biol. 6, 306-329 (1963).
65. Monod, J., Wyman, J. & Changeux, J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12, 88-118 (1965).
66. Del Castillo, J. & Katz, B. Interaction at end-plate receptors between different choline derivatives. Proc. R. Soc. Lond. B 146, 369-381 (1957).
67. Katz, B. & Thesleff, S. A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J. Physiol. (Lond.) 138, 63-80 (1957).
68. Colquhoun, D. in Drug Receptors (ed. Rang, H. P.) 149-182 (Macmillan, London, 1973).
69. Karlin, A. On the application of 'a plausible model' of allosteric proteins to the receptor for acetylcholine. J. Theor. Biol. 16, 306-320 (1967).
70. Thron, C. D. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol. Pharmacol. 9, 1-9 (1973).
71. Leff, P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97 (1995).
72. Cuatrecasas, P. Membrane receptors. Annu. Rev. Biochem. 43, 169-214 (1974).
73. De Lean, A., Stadel, J. M. & Lefkowitz, R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 7108-7117 (1980).
74. 2-dopamine receptor of the anterior pituitary gland. Mol. Pharmacol. 26, 214-227 (1984).
75. Ehlert, F. J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28, 410-421 (1985).
76. Stockton, J. M., Birdsall, N. J. M., Burgen, A. S. V. & Hulme, E. C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23, 551-557 (1983).
77. Lüllman, H., Ohnesorge, F. K., Schauwecker, G.-C. & Wasserman, O. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur. J. Pharmacol. 6, 241-247 (1969).
78. Clark, A. L. & Mitchelson, F. The inhibitory effects of gallamine on muscarinic receptors. Br. J. Pharmacol. 58, 323-331 (1976).
79. Costa, T. & Herz, A. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc. Natl Acad. Sci. USA 86, 7321-7325 (1989).
80. 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636 (1993).
81. Weiss, J. M., Morgan, P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. I. Model description. J. Theor. Biol. 178, 151-167 (1996).
82. 2 receptor. J. Clin. Invest. 91, 1314-1318 (1993).
83. Kumamoto, E. The pharmacology of amino-acid responses in septal neurons. Prog. Neurobiol. 52, 197-259 (1997).
84. A) receptors of a neuroactive steroid that negatively modulates glutamate neurotransmission and augments GABA neurotransmission. Mol. Pharmacol. 60, 732-741 (2001).
85. A receptor research. Synapse 21, 189-274 (1995).
86. Belelli, I., Pistis, I., Peters, J. A. & Lambert, J. J. General anaesthetic action at transmitter-gated inhibitory amino acid receptors. Trends Pharmacol. Sci. 20, 496-502 (1999).
87. Gasior, M., Carter, R. B. & Witkin, J. M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20, 107-112 (1999).
88. Ehlert, F. J., Roeske, W. R., Braestrup, C., Yamamura, S. H. & Yamamura, H. I. γ-Aminobutyric acid regulation of the benzodiazepine receptor: biochemical evidence for pharmacologically different effects of benzodiazepines and propyl β-carboline-3-carboxylate. Eur. J. Pharmacol. 70, 593-595 (1981).
89. Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. & Petersen, E. N. Interaction of convulsive ligands with benzodiazepine receptors. Science 216, 1241-1243 (1982).
90. Maelicke, A. & Albuquerque, E. X. New approach to drug therapy in Alzheimer's dementia. Drug Discov. Today 1, 53-59 (1996).
91. Albuquerque, E. X. et al. Properties of neuronal nicotinic acetylcholine recpeptors: pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280, 1117-1136 (1997).
92. Bouzat, C. & Barrantes, F. J. Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone. Possible allosteric mechanism of channel blockade. J. Biol. Chem. 271, 25835-25841 (1996).
93. Schrattenholz, A. et al. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49, 1-6 (1996).
94. Changeux, J.-P. The TiPS Lecture. The nicotinic acetylcholine receptor: an allosteric protein prototype of ligand-gated ion channels. Trends Pharmacol. Sci. 11, 485-492 (1990).
95. Changeaux, J.-P. & Revah, F. The acetylcholine receptor molecule: allosteric sites and the ion channel. Trends Neurosci. 10, 245-249 (1987).
96. Pagan, O. R. et al, Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. Biochemistry 40, 11121-11130 (2001).
97. Krause, R. M. et al. Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 283-294 (1998).
98. Yamakura, T. & Shimoji, K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 59, 279-298 (1999).
99. Mothet, J. P. et al. D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl Acad. Sci. USA 97, 4926-4931 (2000).
100. Leeson, P. D. & Iversen, L. L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 37, 4053-4067 (1994).
101. Marvizón, J.-C. & Baudry, M. Allosteric interactions and modulator requirement for NMDA receptor function. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 269, 165-175 (1994).
102. 3H]L-689,560 binding to the glycine site of the NMDA receptor from rat brain. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266, 43-50 (1994).
103. 4 purinoceptor: evidence for allosteric interactions of purinoceptor antagonists and monovalent cations with P2X purinoceptors. Mol. Pharmacol. 51, 524-532 (1997).
104. 1 adenosine receptor coupling to G proteins. Biochim. Biophys. Acta 1265, 15-21 (1995).
105. 1 receptor. J. Pharmacol. Exp. Ther. 281, 761-768 (1997).
106. 1 receptor. Biochem. Pharmacol. 61, 137-144 (2001).
107. 1 receptor-dependent and -independent effects of the allosteric enhancer PD81,723. J. Pharmacol. Exp. Ther. 288, 446-454 (1999).
108. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol. 60, 1057-1063 (2001).
109. 1A-adrenergic receptor. Mol. Pharmacol. 57, 436-445 (2000).
110. 1-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation. J. Pharmacol. Exp. Ther. 291, 1164-1171 (1999).
111. 2A-adrenoceptor: allosteric modulation by amilorides. Mol. Pharmacol. 58, 1091-1099 (2000).
112. 2B-adrenergic receptor subtype. Mol. Pharmacol. 39, 481-486 (1991).
113. 2D-adrenoceptor: competitive antagonism and allosteric activation. Br. J. Pharmacol. 130, 1706-1712 (2000).
114. 2+. Mol. Pharmacol. 61, 65-72 (2002).
115. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol. Pharmacol. 53, 1083-1088 (1998).
116. 2+-sensing receptor. Proc. Natl Acad. Sci. USA 97, 4814-4819 (2000).
117. Cox, M. A. et al. Human interferon-inducible 10-kDa protein and human interferon-inducibie T cell-α chemoattractant are allotopic ligands for human CXCR3; differential binding to receptor states. Mol. Pharmacol. 59, 707-715 (2001).
118. Zhao, J. et al. Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J. Exp. Med. 190, 101-111 (1999).
119. Sabroe, I. et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275, 25985-25992 (2000).
120. 2 dopamine recpetors. J. Neurochem. 68, 1990-1997 (1997).
121. 2 dopamine receptors by amilonde and amiloride analogs. Mol. Pharmacol. 50, 1295-1308 (1996).
122. 2-like dopamine receptors through distinct molecular mechanisms. J. Pharmacol. Exp. Ther. 289, 956-964 (1999).
123. Blandin, V., Vigne, P., Breittmayer, J. P. & Frelin, C. Allosteric inhibition of endothelin ETA receptors by 3,5-dibromosalicylic acid. Mol. Pharmacol. 58, 1461-1469 (2000).
124. Talbodec, A. et al. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol. Pharmacol. 57, 797-804 (2000).
125. 5 receptors and CNS disorders. Trends Pharmacol. Sci. 22, 331-337 (2001).
126. Proska, J. & Tucek, S. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 45, 709-717 (1994).
127. Knaus, G. A., Knaus, H. G. & Saria, A. Complex allosteric interaction of heparin with neurokinin-1 receptors. Eur. J. Pharmacol. 207, 267-270 (1991).
128. Speeding, M., Sweetman, A. J. & Weetman, D. F. Antagonism of adenosine 5′-triphosphate-induced relaxation by 2-2′-pyridylisatogen in the taenia of guinea-pig caecum. Br. J. Pharmacol. 53, 575-583 (1975).
129. King, B. F. et al. Potentiation by 2,2′-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br. J. Pharmacol. 117, 1111-1118 (1996).
130. Fillion, G. et al. A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors. Behav. Brain Res. 73, 313-317 (1996).
131. 1B receptor subtype. Ann. NY Acad. Sci. 861, 174-182